Texas Permanent School Fund Decreases Position in Iqvia Holdings Inc (IQV)

Texas Permanent School Fund lowered its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 7.9% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 36,382 shares of the medical research company’s stock after selling 3,116 shares during the period. Texas Permanent School Fund’s holdings in Iqvia were worth $4,720,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Carillon Tower Advisers Inc. boosted its stake in Iqvia by 9.2% during the second quarter. Carillon Tower Advisers Inc. now owns 258,241 shares of the medical research company’s stock valued at $25,777,000 after buying an additional 21,846 shares in the last quarter. Redpoint Investment Management Pty Ltd boosted its stake in Iqvia by 25.0% during the second quarter. Redpoint Investment Management Pty Ltd now owns 13,657 shares of the medical research company’s stock valued at $1,363,000 after buying an additional 2,732 shares in the last quarter. Northern Trust Corp boosted its stake in Iqvia by 7.0% during the second quarter. Northern Trust Corp now owns 1,877,470 shares of the medical research company’s stock valued at $187,408,000 after buying an additional 122,260 shares in the last quarter. FMR LLC boosted its stake in Iqvia by 45.5% during the second quarter. FMR LLC now owns 434,067 shares of the medical research company’s stock valued at $43,329,000 after buying an additional 135,640 shares in the last quarter. Finally, Korea Investment CORP boosted its stake in Iqvia by 83.1% during the second quarter. Korea Investment CORP now owns 28,651 shares of the medical research company’s stock valued at $2,860,000 after buying an additional 13,000 shares in the last quarter. 90.70% of the stock is owned by institutional investors and hedge funds.

Several research analysts recently weighed in on the company. Zacks Investment Research cut Iqvia from a “buy” rating to a “hold” rating in a research note on Thursday. Royal Bank of Canada raised their target price on Iqvia to $137.00 and gave the company an “outperform” rating in a research note on Tuesday, October 23rd. Piper Jaffray Companies raised their target price on Iqvia to $131.00 and gave the company a “neutral” rating in a research note on Tuesday, October 23rd. Barclays upped their target price on Iqvia from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, October 23rd. Finally, UBS Group started coverage on Iqvia in a report on Tuesday, October 9th. They set a “buy” rating for the company. Five analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $131.32.



Shares of NYSE IQV opened at $120.19 on Friday. The firm has a market cap of $24.35 billion, a PE ratio of 23.71, a P/E/G ratio of 1.72 and a beta of 0.70. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.09 and a quick ratio of 1.13. Iqvia Holdings Inc has a 12 month low of $91.57 and a 12 month high of $135.48.

Iqvia (NYSE:IQV) last announced its quarterly earnings data on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.03. The firm had revenue of $2.59 billion during the quarter, compared to the consensus estimate of $2.58 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. On average, research analysts anticipate that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.

In related news, insider Kevin C. Knightly sold 9,216 shares of the stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $126.46, for a total value of $1,165,455.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Robert Parks sold 871 shares of the stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $124.34, for a total value of $108,300.14. The disclosure for this sale can be found here. Over the last three months, insiders sold 602,457 shares of company stock valued at $75,618,723. Company insiders own 6.00% of the company’s stock.

About Iqvia

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Read More: Stock Symbols, CUSIP and Other Stock Identifiers

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply